• Natera announced real-world research presented at ASN Kidney Week 2026 highlighting delayed chronic kidney disease diagnoses and gaps in specialist care.
• Patients experienced substantial diagnostic delays, with kidney function declining before diagnosis; high-risk patients frequently lacked documented nephrology care.
• The findings support earlier evaluation of disease causes, which the company positions its Renasight genetic test to address.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261026646022) on October 26, 2026, and is solely responsible for the information contained therein.